EHA 2022 | TakeAim Leukemia: emavusertib as monotherapy or with azacitidine or venetoclax in R/R AML or MDS
Guillermo Garcia-Manero
• 10 Jun 2022
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the rationale and results of TakeAim Leukemia, a Phase I/IIa dose escalation and cohort expansion study evaluating the safety and clinical activity of the IRAK4 inhibitor emavusertib alone or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (NCT04278768). Overall, the agent showed a promising activity in this patient population, especially in patients with splicing mutations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
